NDAINJECTIONINJECTABLE
Approved
Oct 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
ZOSYN (piperacillin sodium; tazobactam sodium) by Pfizer is [ see microbiology ()] . Approved for older) for the treatment of appendicitis (complicated by rupture, abscess), peritonitis caused by beta-lactamase producing isolates of escherichia coli and 12 more indications. First approved in 1993.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOSYN is a fixed-dose combination of piperacillin (a broad-spectrum beta-lactam antibiotic) and tazobactam (a beta-lactamase inhibitor) administered by injection. It treats serious infections including complicated appendicitis, peritonitis, nosocomial pneumonia, skin/skin structure infections, and pelvic inflammatory disease caused by beta-lactamase producing gram-negative and gram-positive organisms. The tazobactam component protects piperacillin from enzymatic degradation, extending its spectrum against resistant bacteria.
$0.26MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity; brand team likely focused on transition planning and generic defense rather than growth initiatives.
Mechanism of Action
[ see Microbiology ()] .
Worked on ZOSYN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.